High-throughput target trial emulation for Alzheimer’s disease drug repurposing with real-world data
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Target trial emulation is the process of mimicking target randomized trials using real-world data, where effective confounding control for unbiased treatment effect estimation remains a main challenge. Although various approaches have been proposed for this challenge, a systematic evaluation is still lacking. Here we emulated trials for thousands of medications from two large-scale real-world data warehouses, covering over 10 years of clinical records for over 170 million patients, aiming to identify new indications of approved drugs for Alzheimer’s disease. We assessed different propensity score models under the inverse probability of treatment weighting framework and suggested a model selection strategy for improved baseline covariate balancing. We also found that the deep learning-based propensity score model did not necessarily outperform logistic regression-based methods in covariate balancing. Finally, we highlighted five top-ranked drugs (pantoprazole, gabapentin, atorvastatin, fluticasone, and omeprazole) originally intended for other indications with potential benefits for Alzheimer’s patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, the advancement of artificial intelligence (AI)-based computational tools is facilitating drug repurposing, presenting a promising strategy AD drug development.431–433”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [431]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The central role of the propensity score in observational studies for causal effects
ROSENBAUM, P. R., & RUBIN, D. B. (1983) · Biometrika · doi:10.1093/biomet/70.1.41 · Cited by 31,241
Scikit-learn: Machine Learning in Python
(2011) · Journal of Machine Learning Research · doi:10.5555/1953048.2078195 · Cited by 8,539
Austin, P. C. (2009) · Statistics in Medicine · doi:10.1002/sim.3697 · Cited by 6,758 · cited 3×
“We quanti fi ed the balance performance by the standardized mean difference (SMD) 15,16 and the generalization performance by the area under the receiver operating characteristic (AUC).”
Austin, P. C., & Stuart, E. A. (2015) · Statistics in Medicine · doi:10.1002/sim.6607 · Cited by 4,495 · cited 17×
“The goodness-of-balance is measured by the standardized mean difference (SMD) of the covariates ’ prevalence 15,16 , de fi ned as: where x treat , x control 2 R D represent the vector representations of D covariates of the treated group and control group respectively, μ treat , μ control 2 R D are…”
InfluentialA survey of cross-validation procedures for model selection
Arlot, S., & Célisse, A. (2010) · LillOA (Université de Lille (University Of Lille)) · Cited by 3,669
A survey of cross-validation procedures for model selection
Arlot, S., & Celisse, A. (2010) · Statistics Surveys · doi:10.1214/09-ss054 · Cited by 3,522 · cited 1×
“…which splits the data into mutually exclusive training and testing sets and picks the hyper-parameters based on cross-validation on the training set (say, accordingtotheareaunderthereceiveroperatingcharacteristiccurve on predicting treatment assignment) 21,22 , may lead to inferior performance.”
Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available: Table 1.
Hernán, M. A., & Robins, J. M. (2016) · American Journal of Epidemiology · doi:10.1093/aje/kwv254 · Cited by 3,115
When to use the Bonferroni correction
Armstrong, R. A. (2014) · Ophthalmic and Physiological Optics · doi:10.1111/opo.12131 · Cited by 3,031 · cited 1×
“…(aHR 1) of developing AD among MCI patients than comparison groups,(ii)itsdecreasedriskwasreplicatedinbothtwodatasets(EHRs and administrative claims), and (iii) to control for potential false fi ndings, we used the corrected signi fi cance level of 1 : 6×10 (cid:2) 4 by the Bonferroni method 26 .”
Constructing Inverse Probability Weights for Marginal Structural Models
Cole, S. R., & Hernan, M. A. (2008) · American Journal of Epidemiology · doi:10.1093/aje/kwn164 · Cited by 2,796
The Robust Inference for the Cox Proportional Hazards Model
Lin, D. Y., & Wei, L. J. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478874 · Cited by 2,695 · cited 1×
“The adjusted hazard ratio (aHR) and its P value were modeled by the Cox proportional hazard model 58 and the Wald Chi-Square test.”
Research works printed but not linked: 2
- Ke, G. et al. LightGBM: A Highly Efficient Gradient Boosting Decision Tree. in Advances in Neural Information Processing Systems 30 (Curran Associates, Inc., 2017).
- Kingma, D. P. & Ba, J. Adam: A Method for Stochastic Optimization. in 3rd International Conference on Learning Representations, ICLR 2015, San Diego, CA, USA, May 7–9, 2015, Conference Track Proceedings (2015).
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Data-driven identification of post-acute SARS-CoV-2 infection subphenotypes
Zhang, H., Zang, C., Xu, Z., Zhang, Y., Xu, J., Bian, J., Morozyuk, D., Khullar, D., Zhang, Y., Nordvig, A. S., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02116-3 · Cited by 184
Self-citationAlgorithmic fairness in computational medicine
Xu, J., Xiao, Y., Wang, W. H., Ning, Y., Shenkman, E. A., Bian, J., & Wang, F. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2022.104250 · Cited by 170
Self-citationApplications of Artificial Intelligence in Drug Repurposing
Wan, Z., Sun, X., Li, Y., Chu, T., Hao, X., Cao, Y., & Zhang, P. (2025) · Advanced Science · doi:10.1002/advs.202411325 · Cited by 126
Toumaj, S., Heidari, A., Shahhosseini, R., & Navimipour, N. J. (2024) · Artificial Intelligence Review · doi:10.1007/s10462-024-11041-5 · Cited by 83
Metadata
- Authors
- Zang, C., Zhang, H., Xu, J., Zhang, H., Fouladvand, S., Havaldar, S., Cheng, F., Chen, K., Chen, Y., Glicksberg, B. S., Chen, J., Bian, J., & Wang, F.
- Affiliations
- Weill Cornell Medicine (US)
- University of Florida Health (US)
- University of Kentucky (US)
- Icahn School of Medicine at Mount Sinai (US)
- Cleveland Clinic (US)
- University of Connecticut (US)
- University of Pennsylvania (US)
- Corresponding author
- Wang, Fei
- ORCID
- Venue
- Nature Communications
- Published
- 2023-12-11
- Volume
- 14
- Issue
- 1
- Pages
- 8180-8180
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC10713627
- OpenAlex
- W4389549989
- Cited by
- 69
- References
- 63
- Citations by year
- 2026: 22 · 2025: 33 · 2024: 13
- FWCI
- 13.82
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Science Foundation (1750326)
- International Business Machines Corporation
- National Institutes of Health (1rf1ag084178-01, RF1G077820, 1rf1ag077820-01a1)
- National Institute on Aging (R56AG074001, R56AG069880, R01AG066707, R56AG074604, RF1AG082211, RF1 AG084178, RF1AG072449, RF1AG059319, R21AG083003, RF1AG077820, R21AG068717, K08AG065463, R01AG083039, R01AG084236, R01AG084250, R01AG080991, R01AG080624, R01AG082118, R01AG073435, P30AG072946, R01AG076448, R01AG076234, U01AG073323)
- National Institute of Mental Health (R01MH124740)
- National Institute on Drug Abuse (UM1DA049406)
- National Cancer Institute (R01CA246418, R21CA245858)
- National Institute of General Medical Sciences (P20GM109025)
- National Institute of Allergy and Infectious Diseases (R01AI172875)
- National Institute of Neurological Disorders and Stroke (RF1NS133812)
- U.S. National Library of Medicine (R01LM013519, R01LM014344)
- Topics
- Physical Sciences › Mathematics › Statistics and Probability › Advanced Causal Inference Techniques
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Physical Sciences › Computer Science › Artificial Intelligence › Machine Learning in Healthcare
- Keywords
- target trial emulation, Alzheimer's disease, drug repurposing, real-world data, propensity score matching, inverse probability of treatment weighting, confounding adjustment, covariate balancing, model selection, pantoprazole, gabapentin, atorvastatin, fluticasone, omeprazole
- MeSH terms
- Atorvastatin, Alzheimer Disease, Humans, Propensity Score, Drug Repositioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High-throughput target trial emulation for Alzheimer’s disease drug repurposing with real-world data. https://app.cochat.ai/papers/10.1038/s41467-023-43929-1
- The paper
- Zang, C., Zhang, H., Xu, J., Zhang, H., Fouladvand, S., Havaldar, S., Cheng, F., Chen, K., Chen, Y., Glicksberg, B. S., Chen, J., Bian, J., & Wang, F. (2023). High-throughput target trial emulation for Alzheimer’s disease drug repurposing with real-world data. Nature Communications. https://doi.org/10.1038/s41467-023-43929-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.